Mar 12th 2013 - Edison Investment Research today published a report on Ablynx entitled "Focus Moves To Partnering". In summary, the report says:
Ablynx’s investment case in the near term hinges on its ability to partner its IL-6R Nanobody, ALX-0061, using the final results from the Phase I/II study in rheumatoid arthritis (RA). The 24-week data suggests that ALX-0061 might have a superior efficacy and safety profile to Roche’s tocilizumab (Actemra, an IL-6R monoclonal antibody) and other IL-6 inhibitors in development. The partnering of ALX-0061 could still be challenging because of the competitive nature of RA, but Ablynx has raised €31.5m to maintain momentum in the programme. We value the company at €431m, which rises to €497m if ALX-0061 is out-licensed.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »